-
公开(公告)号：CL2023001509A1
公开(公告)日：2024-01-19
申请号：CL2023001509
申请日：2023-05-25
Applicant: UCB BIOPHARMA SRL
Inventor： RALPH ADAMS , JOSEPH MICHAEL DAVID RASTRICK , JOHN PAUL SILVA , KERRY LOUISE TYSON , PETER CHARLES ELLIOTT , SEPPE FRANS ROMAN LEYSEN , ZAINAB AHDASH , DANIEL JOHN LIGHTWOOD , ROGER THOMAS PALFRAMAN , SEEMA MAYANK , ANDREA JULIE CROSBY , EMILY MARY CAIRISTINE BARRY
IPC: C07K16/24
Abstract: La presente invención se refiere a anticuerpos que se unen a IL13 e IL22. La invención proporciona nuevos anticuerpos multiespecíficos que se unen tanto a IL13 como a IL22 y a composiciones que comprenden un anticuerpo que se une a IL13 y un anticuerpo que se une a IL22. La invención se refiere además a usos terapéuticos de la combinación de anticuerpos anti-IL13 y anti-IL22 y anticuerpos multi-específicos que se unen tanto a IL13 como a IL22.
-
公开(公告)号：BR112022015281A2
公开(公告)日：2022-09-20
申请号：BR112022015281
申请日：2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor： NEESHA DEDI , PETER CHARLES ELLIOTT , SEPPE FRANS ROMAN LEYSEN , SEAN MASON , DAVID JAMES MCMILLAN , GILLIAN CLAIRE NESS , NICCOLO PENGO , MARTIN ANTHONY REDHEAD , ALISON TURNER , KERRY LOUISE TYSON
Abstract: ANTICORPOS CONTRA KLK5. A presente invenção se refere a anticorpos que ligam e inibem KLK5 e métodos de usar os mesmos para tratar doenças causadas pelo desequilíbrio de KLK5. Em particular, a presente invenção se refere a anticorpos inibidores da ligação de KLK5 e seu uso no tratamento da doença de Netherton, dermatite atópica e câncer.
-
Patent Agency Ranking
公开(公告)号：BR112022015279A2
公开(公告)日：2022-09-20
申请号：BR112022015279
申请日：2021-02-01
Applicant: UCB BIOPHARMA SRL
Inventor： NEESHA DEDI , PETER CHARLES ELLIOTT , SEPPE FRANS ROMAN LEYSEN , SEAN MASON , DAVID JAMES MCMILLAN , GILLIAN CLAIRE NESS , NICCOLO PENGO , MARTIN ANTHONY REDHEAD , ALISON TURNER , KERRY LOUISE TYSON
Abstract: ANTICORPOS CONTRA KLK5. A presente invenção se refere a anticorpos que ligam e inibem KLK5 e métodos de usar os mesmos para tratar doenças causadas pelo desequilíbrio de KLK5. Em particular, a presente invenção se refere a anticorpos inibidores da ligação de KLK5 e seu uso no tratamento da doença de Netherton, dermatite atópica e câncer.
-
公开(公告)号：ZA202003414B
公开(公告)日：2022-03-30
申请号：ZA202003414
申请日：2020-06-08
Applicant: UCB BIOPHARMA SRL
Inventor： PATRICK DOWNEY , KERRY LOUISE TYSON , MARCO KRIEK , LORENZO DE LICHTERVELDE , DANIEL JOHN LIGHTWOOD , DAVID JAMES MCMILLAN , PETER CHARLES ELLIOTT , TERENCE SEWARD BAKER
Abstract: The present invention relates to alpha synuclein binding antibodies and fragments thereof capable of binding alpha synuclein as a monomer and in fibrils and preventing alpha synuclein aggregation induced by alpha synuclein fibrils. The antibodies of the present invention are for use in the treatment of alpha synucleinopathies, including Parkinson's disease.
-
公开(公告)号：ZA202309815B
公开(公告)日：2025-03-26
申请号：ZA202309815
申请日：2023-10-20
Applicant: UCB BIOPHARMA SRL
Inventor： DANIEL JOHN LIGHTWOOD , IRENA KADIU , PALLAVI BHATTA , ANASTASIOS SPILIOTOPOULOS , PETER CHARLES ELLIOTT , JAMES MARTIN KEANEY , SILVIA L DELKER , JAN ABENDROTH
Abstract: The present invention relates to antibodies binding to TREM1 and inhibiting its interaction with one or more of its natural ligands. Specific examples of such antibodies are provided. The therapeutic uses of the antibodies and methods of generating such are also provided.
-
公开(公告)号：ZA202305329B
公开(公告)日：2024-09-25
申请号：ZA202305329
申请日：2023-05-16
Applicant: UCB BIOPHARMA SRL
Inventor： JOSEPH MICHAEL DAVID RASTRICK , JOHN PAUL SILVA , DANIEL JOHN LIGHTWOOD , RALPH ADAMS , ROGER THOMAS PALFRAMAN , KERRY LOUISE TYSON , PETER CHARLES ELLIOTT , SEEMA MAYANK , ANDREA JULIE CROSBY , EMILY MARY CAIRISTINE BARRY , SEPPE FRANS ROMAN LEYSEN , ZAINAB AHDASH
Abstract: The present invention relates to antibodies binding to IL13 and IL22. The invention provides novel multi-specific antibodies that bind to both IL13 and IL22 and compositions comprising an antibody that binds to IL13 and an antibody that binds to IL22. The invention further relates to therapeutic uses of the combination of anti-IL13 and anti-IL22 antibodies and multi-specific antibodies that bind to both IL13 and IL22.
-
公开(公告)号：BR112020010508A2
公开(公告)日：2020-11-24
申请号：BR112020010508
申请日：2018-12-13
Applicant: UCB BIOPHARMA SRL
Inventor： DANIEL JOHN LIGHTWOOD , DAVID JAMES MCMILLAN , KERRY LOUISE TYSON , LORENZO DE LICHTERVELDE , MARCO KRIEK , PATRICK DOWNEY , PETER CHARLES ELLIOTT , TERENCE SEWARD BAKER
IPC: A61K39/395 , A61K39/00 , A61P25/16 , A61P25/28 , C07K16/28
Abstract: a presente invenção se refere a anticorpos de ligação à alfa-sinucleína e fragmentos dos mesmos, capazes de se ligarem à alfa-sinucleína como um monômero e em fibrilas e previnem a agregação de alfa-sinucleína induzida por fibrilas de alfa-sinucleína. os anticorpos da presente invenção são para uso no tratamento de alfa-sinucleinopatias, incluindo a doença de parkinson.
-
-
-
-
-
-
Search Results
7
records
(took 0.02 seconds)
